Q-omics provides the consensus-scored MT1X profile across patient tissues and cancer cell-line models. MT1X expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, MT1X is differentially expressed in 15, with the highest sampling consensus in KICH. Additionally, MT1X RNA expression shows 15,341 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight HNSC, KICH, and TGCT as cancer lineages where MT1X shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MT1X — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MT1X survival associations across molecular data types. MT1X RNA expression shows survival associations in the most cancer types (25), followed by mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MT1X RNA expression–survival associations across cancer types. High MT1X expression shows unfavorable associations in HNSC, BLCA, UCS, KIRP and KIRC, but favorable associations in SKCM. The HNSC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for MT1X RNA expression.
This table summarizes MT1X tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 5. The strongest signals are observed in THCA for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for MT1X. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MT1X shows lower tumor expression in KICH, COAD, THCA, LIHC, KIRP and KIRC. The KICH box plot shows higher MT1X RNA expression in normal versus tumor tissue (log2 FC = −5.130, t-test p < 0.001).
This table shows molecular features associated with MT1X in patient tissues and cancer cell lines. In patient samples, MT1X shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, MT1X RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in OVARY and LARGE_INTESTINE.
